Immunotherapy for the Treatment of Cancer

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia and multiple solid tumors.

View Product Pipeline


GT Biopharma, Inc. a targeted immunotherapies company with close to market treatments for Central Nervous System diseases.


Latest News

GT Biopharma Announces Postive Results For Two Next Generation Trikes In Solid Tumors
Sep 13, 2018 • 8:36 EDT | Read More

GT Biopharma's Chairman and Chief Executive Officer Raymond W Urbanski, M.D., Ph.D Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration
Aug 30, 2018 • 8:00 EDT | Read More


GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range